Swedish researchers have identified a potential link between newer blood-thinning medications and a slower rate of cognitive decline in Alzheimer's patients. The study, published in the European Heart Journal, suggests that improving blood flow to the brain may offer neuroprotective benefits for those with atrial fibrillation.
The 7,308-person Swedish study on atrial fibrillation
Experts at Karolinska University Hospital conducted a large-scale analysis of 7,308 individuals living with both atrial fibrillation and Alzheimer's disease .. Using data from the Swedish Register for Cognitive Disorders, the research team monitored how different medication regimens affected brain health over time.
The researchers assessed cognitive stability by testing patients on several critical metrics, including memory, language, and motor skills. According to the study, the primary goal was to determine if the type of anticoagulant used could influence the progression of memory-robbing symptoms in this specific patient population.
A 1% margin in memory scores
The study found that patients using newer anticoagulants, such as rivaroxaban, experienced a slower decline in cognitive function compared to those using the older drug warfarin or those receiving no treatment at all. As reported in the European Heart Journal, the difference was modest in the short term, with newer drug users scoring just under 1% higher on memoory tests after one year.
Despite the small annual margin, Professor Nanbo Zhu, a co-author of the study, argued that these incremental gains could become significantly more impactful over a longer period.. Dr. Maria Eriksdotter, the study's lead author, noted that the treatment likely works by improving cerebral blood flow and reducing the small-scale damage within the brain that often accompanies vascular issues.
The 1.4 million person dementia projection in the UK
The implications of this research are particularly relevant for the United Kingdom, where approximately 1 million people are currently living with dementia. This figure is projected to rise to 1.4 million by 2040, making the search for preventative or slowing treatments a public health priority. Currently, more than 1.6 million people in the UK take blood thinners to manage atrial fibrillation, a condition that can increase dementia risk by as much as a third.
This research follows similar findings from NYU Langone Health, which suggested that managing blood pressure, diabetes, and smoking habits in middle age can provide up to 13 additional years of dementia-free life. Both studies underscore the critical link between vascular health and long-term cognitive preservation.
Can these drugs benefit patients without atrial fibrillation?
While the results are promising, several critical questions remain unanswered. The researchers explicitly stopped short of recommending these anticoagulants for patients who do not have atrial fibrillation, and it remains unclear if the cognitive benefits extend to the broader population. Furthermore, the study noted that while newer drugs showed promise, the older alternative, warfarin, still carries a higher risk of major bleeding compared to no treatment.
Dr. Richard Oakley of the Alzheimer's Society welcomed the findings but emphasized the need for further investigation. As the report indicates, more clinical studies are required before doctors can confidently prescribe these specific anticoagulants based solely on their potential to slow Alzheimer's progression .
Comments 0